| Literature DB >> 30756358 |
Jasmine A Luzum1,2, Joseph D English3, Umair S Ahmad4,5, Jessie W Sun6, Benjamin D Canan7, Wolfgang Sadee6, Joseph P Kitzmiller8,6, Philip F Binkley5.
Abstract
Two common genetic polymorphisms in the beta-1 adrenergic receptor (ADRB1 Ser49Gly [rs1801252] and Arg389Gly [rs1801253]) significantly affect receptor function in vitro. The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure. Patients with heart failure and baseline LVEF ≤ 40% were genotyped (n = 98), and retrospective chart review assessed the primary outcome of LVEF recovery to ≥ 40%. Un/adjusted logistic regression models revealed that Ser49Gly, but not Arg389Gly, was significantly associated with LVEF recovery in a dominant genetic model. The adjusted odds ratio for Ser49 was 8.2 (95% CI = 2.1-32.9; p = 0.003), and it was the strongest predictor of LVEF recovery among multiple clinical variables. In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.Entities:
Keywords: Beta-1 adrenergic receptor; Beta-blocker; Genetics; Heart failure; Left ventricular ejection fraction; Polymorphism
Mesh：
Substances：
Year: 2019 PMID： 30756358 PMCID： PMC6690812 DOI： 10.1007/s12265-019-09866-5
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132